Flashbacks and HPPD: A Clinical-oriented Concise Review
This review (2014) examines the cause of flashbacks or Hallucinogen Persisting Perception Disorder (HPPD), which represents a cluster of recurrent visual disturbances which have been reported to persist after the acute phase of psychedelics, such as LSD. The authors delineate HPPD type I disorder: short-term, non-distressing, benign, and reversible state accompanied by a pleasant affect, and type II: long-term, distressing, pervasive, either slowly reversible or irreversible, non-benign state accompanied by an unpleasant affect. Although the prevalence of HPPD remains understudied, the authors review a large variety of medications that may alleviate the symptoms of this condition.
Authors
- Lerner, A. G.
Published
Abstract
A unique characteristic of LSD, LSD-like and substances with hallucinogenic properties is the recurrence of some or all the hallucinogenic symptoms which had appeared during the intoxication after the immediate effects of the substance had worn off. This recurring syndrome, mainly visual, is not clearly understood. The terms Flashback and Hallucinogen Persisting Perception Disorder (HPPD) have been used interchangeably in the professional literature. We have observed at least two different recurrent syndromes, the first Flashback Type we refer to as HPPD I, a generally short-term, non-distressing, benign and reversible state accompanied by a pleasant affect. In contrast, the second HPPD Type we refer to as HPPD II, a generally long-term, distressing, pervasive, either slowly reversible or irreversible, non-benign state accompanied by an unpleasant affect. HPPD I and II appear to be part of a broad spectrum of non-psychopathological and psychopathological states reported by hallucinogen users. HPPD I and II may be clinically characterized by prodromal symptoms, onset, content of visual imagery, precipitators, frequency, duration and intensity of perceptual recurrences, severity, course, differential diagnosis, accompanying mood and affect, insight and remission. Pharmacological therapy with or without preceding or following co-occurring psychiatric disorders have been shown to ameliorate this syndrome. A large variety of medications may be utilized to alleviate this condition, but with differential results suggesting several subtypes. The purpose of this manuscript is to provide a clinical-oriented, comprehensive and concise review to treating psychiatrists.
Research Summary of 'Flashbacks and HPPD: A Clinical-oriented Concise Review'
Introduction
Hallucinogens include a range of natural and synthetic substances that produce transient intoxications marked chiefly by visual perceptual disturbances, often called "trips". A striking feature described with LSD and LSD-like agents is the recurrence, after intoxication has ended, of some or all perceptual symptoms experienced during the original episode. Prior work has implicated a wide variety of substances beyond LSD—psilocybin, mescaline, cannabis and synthetic cannabinoids, MDMA, PCP, dextromethorphan, ketamine and others—but the pathophysiology and clinical boundaries of these recurrent phenomena remain poorly specified. This review seeks to clarify terminology and clinical characterisation of recurrent substance-associated perceptual disturbances. Lerner and colleagues propose a two-part clinical taxonomy—HPPD I (benign, short-lived, non-distressing "flashbacks") and HPPD II (chronic, distressing, functionally impairing persisting perceptual disorder)—and aim to summarise hypothesised mechanisms, typical phenomenology, precipitants, differential diagnosis and pharmacological management for clinicians treating these presentations. The authors position the manuscript as a concise, clinically oriented synthesis to guide psychiatrists encountering such cases.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compound
- APA Citation
(2014). Flashbacks and HPPD: A Clinical-oriented Concise Review. The Israel Journal of Psychiatry and Related Sciences; Jerusalem.
References (2)
Papers cited by this study that are also in Blossom
Abraham, H. D., Aldridge, A. M., Gogia, P. · Neuropsychopharmacology (1996)
Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (2003)
Cited By (6)
Papers in Blossom that reference this study
Dourron, H. M., Nichols, C. D., Simonsson, O. et al. · Psychopharmacology (2023)
Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. et al. · Frontiers in Psychiatry (2022)
Doyle, M. A., Ling, S., Lui, L. M. W. et al. · Expert Opinion on Drug Safety (2022)
Müller, F., Holze, F., Becker, A. M. et al. · Psychopharmacology (2022)
Ermentrout, G. B., Vis, P. J., Goudriaan, A. E. et al. · Frontiers in Neuroscience (2021)
Martinotti, G., Santacroce, R., Pettorruso, M. et al. · Brain Sciences (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.